← Bausch Health Companies overview

Bausch Health Companies vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bausch Health Companies Inc (BHC)

Q3 2026
▲4

BHC's core business is beating expectations and expanding abroad

  • Q2 earnings blow past estimates, guidance raised BHC reported Q2 adjusted earnings of $1.26 per share, far above the 96-cent estimate, on revenue up 13% to $2.85 billion. It raised full-year 2026 revenue and profit guidance. Strong results make the company look healthier and more valuable, pushing the stock up sharply.

    This is the single biggest new force behind BHC's move, directly driving the 28% share surge.

  • Salix and Solta drive the growth The Salix stomach-drug business grew 21%, with Xifaxan up 26%, and Solta Medical aesthetics jumped 38%. These fast-growing segments are the engine of BHC's results, showing its core products still have strong demand and can keep lifting profit.

    Explains which parts of the business are actually powering the earnings beat, not just the headline number.

  • PrOKEDI added to Quebec's public drug list BHC's schizophrenia drug PrOKEDI was listed on Quebec's RAMQ formulary, meaning the province's public health plan will now pay for it. This is a step toward real sales in Canada and shows the company can win reimbursement for new products.

    A concrete regulatory win that opens a new paying market for a BHC product.

  • Skincare partnership expands into new markets BHC extended its YUN probiotic skincare deal into Mexico and five more Central/Eastern European and Central Asian markets, adding to the original Poland launch. More countries mean more product sales and a wider dermatology footprint, though this segment is currently flat.

    Shows a new international growth avenue, but one that is still small relative to the core earnings story.

August 2026
▲4

BHC's core business is beating expectations and expanding abroad

  • Q2 earnings blow past estimates, guidance raised BHC reported Q2 adjusted earnings of $1.26 per share, far above the 96-cent estimate, on revenue up 13% to $2.85 billion. It raised full-year 2026 revenue and profit guidance. Strong results make the company look healthier and more valuable, pushing the stock up sharply.

    This is the single biggest new force behind BHC's move, directly driving the 28% share surge.

  • Salix and Solta drive the growth The Salix stomach-drug business grew 21%, with Xifaxan up 26%, and Solta Medical aesthetics jumped 38%. These fast-growing segments are the engine of BHC's results, showing its core products still have strong demand and can keep lifting profit.

    Explains which parts of the business are actually powering the earnings beat, not just the headline number.

  • PrOKEDI added to Quebec's public drug list BHC's schizophrenia drug PrOKEDI was listed on Quebec's RAMQ formulary, meaning the province's public health plan will now pay for it. This is a step toward real sales in Canada and shows the company can win reimbursement for new products.

    A concrete regulatory win that opens a new paying market for a BHC product.

  • Skincare partnership expands into new markets BHC extended its YUN probiotic skincare deal into Mexico and five more Central/Eastern European and Central Asian markets, adding to the original Poland launch. More countries mean more product sales and a wider dermatology footprint, though this segment is currently flat.

    Shows a new international growth avenue, but one that is still small relative to the core earnings story.

Latest
▲4

BHC's core business is beating expectations and expanding abroad

  • Q2 earnings blow past estimates, guidance raised BHC reported Q2 adjusted earnings of $1.26 per share, far above the 96-cent estimate, on revenue up 13% to $2.85 billion. It raised full-year 2026 revenue and profit guidance. Strong results make the company look healthier and more valuable, pushing the stock up sharply.

    This is the single biggest new force behind BHC's move, directly driving the 28% share surge.

  • Salix and Solta drive the growth The Salix stomach-drug business grew 21%, with Xifaxan up 26%, and Solta Medical aesthetics jumped 38%. These fast-growing segments are the engine of BHC's results, showing its core products still have strong demand and can keep lifting profit.

    Explains which parts of the business are actually powering the earnings beat, not just the headline number.

  • PrOKEDI added to Quebec's public drug list BHC's schizophrenia drug PrOKEDI was listed on Quebec's RAMQ formulary, meaning the province's public health plan will now pay for it. This is a step toward real sales in Canada and shows the company can win reimbursement for new products.

    A concrete regulatory win that opens a new paying market for a BHC product.

  • Skincare partnership expands into new markets BHC extended its YUN probiotic skincare deal into Mexico and five more Central/Eastern European and Central Asian markets, adding to the original Poland launch. More countries mean more product sales and a wider dermatology footprint, though this segment is currently flat.

    Shows a new international growth avenue, but one that is still small relative to the core earnings story.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.